Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Liabilities (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Total Liabilities for 9 consecutive years, with $86.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 29.08% year-over-year to $86.0 million, compared with a TTM value of $86.0 million through Dec 2025, down 29.08%, and an annual FY2025 reading of $86.0 million, down 29.08% over the prior year.
  • Total Liabilities was $86.0 million for Q4 2025 at Puma Biotechnology, down from $87.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $242.2 million in Q1 2021 and bottomed at $86.0 million in Q4 2025.
  • Average Total Liabilities over 5 years is $166.0 million, with a median of $170.3 million recorded in 2023.
  • The sharpest move saw Total Liabilities increased 12.06% in 2021, then tumbled 42.36% in 2025.
  • Year by year, Total Liabilities stood at $229.0 million in 2021, then dropped by 12.48% to $200.5 million in 2022, then dropped by 11.66% to $177.1 million in 2023, then crashed by 31.55% to $121.2 million in 2024, then fell by 29.08% to $86.0 million in 2025.
  • Business Quant data shows Total Liabilities for PBYI at $86.0 million in Q4 2025, $87.6 million in Q3 2025, and $90.2 million in Q2 2025.